| Angioedemas, Hereditary
Kalbitor vs Sajazir
Side-by-side clinical, coverage, and cost comparison for angioedemas, hereditary.Deep comparison between: Kalbitor vs Sajazir with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSajazir has a higher rate of injection site reactions vs Kalbitor based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sajazir but not Kalbitor, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kalbitor
Sajazir
At A Glance
SC injection
As needed
Plasma kallikrein inhibitor
SC injection
As needed
Bradykinin B2 receptor antagonist
Indications
- Angioedemas, Hereditary
- Angioedemas, Hereditary
Dosing
Angioedemas, Hereditary 30 mg (3 mL) subcutaneously in three 10 mg (1 mL) injections per attack; an additional 30 mg may be administered within 24 hours if the attack persists.
Angioedemas, Hereditary 30 mg SC injection in the abdominal area; additional doses at intervals of at least 6 hours if response is inadequate or symptoms recur; no more than 3 doses in 24 hours.
Contraindications
- Known clinical hypersensitivity to KALBITOR
—
Adverse Reactions
Most common (>=3%) Headache, nausea, diarrhea, pyrexia, injection site reactions, nasopharyngitis
Serious Hypersensitivity reactions including anaphylaxis
Postmarketing Similar adverse reactions as observed in clinical trials
Most common (>1%) Injection site reactions, pyrexia, transaminase increased, dizziness
Postmarketing Urticaria
Pharmacology
Plasma kallikrein inhibitor; ecallantide is a potent, selective, reversible inhibitor of plasma kallikrein that blocks its binding site, reducing the conversion of HMW kininogen to bradykinin and thereby treating symptoms during acute episodic attacks of HAE.
Icatibant is a competitive antagonist selective for the bradykinin B2 receptor; by blocking bradykinin binding to the B2 receptor, it treats the localized swelling, inflammation, and pain of acute HAE attacks caused by C1-esterase-inhibitor deficiency-driven excess bradykinin production.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kalbitor
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Sajazir
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Kalbitor
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Sajazir
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Kalbitor
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Sajazir
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Hereditary Angioedema - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KalbitorView full Kalbitor profile
SajazirView full Sajazir profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.